Half-year report · HY
4587.TEDINET S100YVU6
Period2026-01-01 → 2026-06-30
Filed2026-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.2bn | 2026-01-01 → 2026-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥18.5bn | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥8.5bn | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Operating income | −¥2.5bn | 2026-01-01 → 2026-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥2.6bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥2.7bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥5.3bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥2.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥2.0bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥3.7bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥2.0bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥3.7bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥72.2bn | at 2026-06-30 | Cons. | Assets IFRS |
| Total assets | ¥77.0bn | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥78.5bn | at 2025-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥23.7bn | at 2026-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥25.5bn | at 2025-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥48.6bn | at 2026-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥51.5bn | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥53.7bn | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥56.8bn | at 2024-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥48.6bn | at 2026-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥51.5bn | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥53.7bn | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥23.6bn | at 2026-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥28.7bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥33.3bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥48.1bn | at 2024-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥1.8bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥13.3bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥11.0bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥614m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥2.7bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥4.1bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥2.5bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-15.51 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-28.99 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-15.51 | 2026-01-01 → 2026-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-28.99 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 67.2% | at 2026-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 66.9% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.3% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2026-01-01 → 2026-06-30 | −¥512m |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-01 → 2026-06-30 | −¥512m |
| Drug Discovery And Development Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥1.2bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥1.2bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥2.7bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥8.5bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥8.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥512m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥242m |
| —segment total | revenue | 2026-01-01 → 2026-06-30 | ¥9.7bn |
| —segment total | revenue external | 2026-01-01 → 2026-06-30 | ¥9.2bn |
| —segment total | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥512m |
| —segment total | segment profit | 2026-01-01 → 2026-06-30 | −¥2.5bn |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥453m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥453m |
| Drug Discovery And Development Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥761m |
| Drug Discovery And Development Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥761m |
| Drug Discovery And Development Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥3.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥8.2bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥7.8bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥436m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥9.0bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | −¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 571
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest expenses ope cf IFRS | Prior1InterimDuration | 177520000 | JPY |
| Interest expenses ope cf IFRS | InterimDuration | 251597000 | JPY |
| Foreign exchange loss gain ope cf IFRS | Prior1InterimDuration | 70404000 | JPY |
| Foreign exchange loss gain ope cf IFRS | InterimDuration | -63810000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | Prior1InterimDuration | 31905000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | InterimDuration | 1323000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1InterimDuration | 787096000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | InterimDuration | 1370113000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1InterimDuration | -395085000 | JPY |
| Decrease increase in inventories ope cf IFRS | InterimDuration | -486528000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1InterimDuration | -1799410000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | InterimDuration | -736544000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | Prior1InterimDuration | -21502000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | InterimDuration | -6454000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1InterimDuration | 199038000 | JPY |
| Other changes in working capital ope cf IFRS | InterimDuration | -302883000 | JPY |
| Subtotal ope cf IFRS | Prior1InterimDuration | -2899473000 | JPY |
| Subtotal ope cf IFRS | InterimDuration | -1703712000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1InterimDuration | 162294000 | JPY |
| Interest and dividends received ope cf IFRS | InterimDuration | 69574000 | JPY |
| Interest paid ope cf IFRS | Prior1InterimDuration | -153366000 | JPY |
| Interest paid ope cf IFRS | InterimDuration | -185539000 | JPY |
| Income taxes paid ope cf IFRS | Prior1InterimDuration | -8062023000 | JPY |
| Income taxes paid ope cf IFRS | InterimDuration | -787000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1InterimDuration | -10952568000 | JPY |
| Net cash provided by used in operating activities IFRS | InterimDuration | -1820465000 | JPY |
| Purchase of investment securities inv cf IFRS | Prior1InterimDuration | -300000000 | JPY |
| Purchase of investment securities inv cf IFRS | InterimDuration | － | JPY |
| Collection of loans receivable inv cf IFRS | Prior1InterimDuration | 3123000 | JPY |
| Collection of loans receivable inv cf IFRS | InterimDuration | 3123000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1InterimDuration | -912673000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | InterimDuration | -516604000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1InterimDuration | -82220000 | JPY |
| Purchase of intangible assets inv cf IFRS | InterimDuration | -122903000 | JPY |
| Other inv cf IFRS | Prior1InterimDuration | 4249000 | JPY |
| Other inv cf IFRS | InterimDuration | 22513000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1InterimDuration | -1287521000 | JPY |
| Net cash provided by used in investing activities IFRS | InterimDuration | -613871000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1InterimDuration | － | JPY |
| Proceeds from long term borrowings fin cf IFRS | InterimDuration | 16440000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1InterimDuration | -1320000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | InterimDuration | -17760000000 | JPY |
| Repayments of installment payables fin cf IFRS | Prior1InterimDuration | － | JPY |
| Repayments of installment payables fin cf IFRS | InterimDuration | -107788000 | JPY |
| Payments of borrowing fee fin cf IFRS | Prior1InterimDuration | － | JPY |
| Payments of borrowing fee fin cf IFRS | InterimDuration | -98640000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1InterimDuration | -198307000 | JPY |
| Repayments of lease obligations fin cf IFRS | InterimDuration | -185362000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1InterimDuration | -960908000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | InterimDuration | -997795000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |